*FREENOME: ANNOUNCES EXCLUSIVE AGREEMENT WITH ROCHE TO EXPAND TECHNOLOGY COLLABORATION, DEVELOP AND COMMERCIALIZE CANCER SCREENING TESTS OUTSIDE U.S.
*FREENOME: RETAINS RIGHTS TO EX-U.S. CENTRALIZED TESTING AS WELL AS ALL U.S. RIGHTS, SUBJECT TO ITS PRE-EXISTING LICENSE TO EXACT SCIENCES
*FREENOME: POTENTIALLY $200+ MILLION AGREEMENT INCLUDES $75 MILLION EQUITY INSTRUMENT, MILESTONE PAYMENTS & ROYALTIES ON EX-U.S. TEST SALES
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 18-NOV-202514:00:06.74 GMT